Tuberculosis, one of humanity's oldest and most relentless adversaries, claims over a million lives each year and leaves millions more with lungs permanently scarred by the battle. Researchers at Johns Hopkins Medicine have discovered that navitoclax, a drug developed to fight cancer, may help the body reclaim control of how infected cells die — steering them away from destructive chaos and toward orderly resolution. By combining this experimental agent with standard antibiotics in mouse models, scientists observed a dramatic reduction in lung damage and bacterial burden, opening a door that h
Cancer drug shows promise in boosting TB treatment, reducing lung damage
Tuberculosis affects tens of millions globally, causing 1.25 million deaths annually and leaving survivors with permanent lung dysfunction and post-TB lung disease.
A controlled death, not a bomb blast, inside the lung
Mark
Why does tuberculosis bacteria want to kill infected cells in such a destructive way? Wouldn't it be better for the bacteria to keep the cell alive?
Mimi
The bacteria doesn't care about the cell itself—it cares about survival. Necrosis creates chaos and inflammation, which actually helps the bacteria hide from the immune system. It's like setting a fire to cover your tracks.
Mark
So navitoclax is essentially forcing the bacteria's host cells to die cleanly instead of messily?
Mimi
Exactly. By blocking the proteins the bacteria uses to prevent controlled cell death, navitoclax tips the balance back toward apoptosis. A clean death means the immune system can clear away the debris and the bacteria more efficiently.
Mark
The mouse results show a 16-fold improvement in killing bacteria. That's enormous. Why hasn't this been tried before?
Mimi
Host-directed therapies are relatively new thinking in infectious disease. For decades, doctors focused on killing bacteria directly with antibiotics. The idea of working with the body's own cell death machinery is a different paradigm—and it required the right drug to test it with.
Mark
What's the biggest risk in moving this to human trials?
Mimi
Safety, primarily. Navitoclax is a cancer drug, and cancer cells also rely on blocking apoptosis. We need to make sure that when we're promoting cell death in TB-infected lungs, we're not harming healthy tissue or causing other problems.
Mark
If this works, could it actually shorten TB treatment from six months?
Mimi
That's the hope. If you're killing bacteria 16 times more effectively, theoretically you might need less time. But that's a question only human trials can answer. The real prize, though, might be preventing the lung scarring that haunts TB survivors for life.
Der Puls
- Tuberculosis remains the world's deadliest infectious disease, killing 1.25 million people in 2023 alone while current treatments are long, costly, and leave survivors with lasting lung damage.
- The bacteria survive by hijacking infected cells, forcing a violent, chaotic form of death that destroys lung tissue and creates hidden sanctuaries where the pathogen can multiply unchecked.
- Navitoclax disrupts this strategy by restoring the body's natural, controlled cell-death pathway — essentially teaching the immune system to demolish infected cells cleanly rather than explosively.
- In mouse studies, the drug combined with standard antibiotics cut destructive lung lesions by 40%, reduced lung scarring by 40%, and cleared bacteria 16 times more effectively than antibiotics alone.
- The approach could also offer a lifeline to patients with drug-resistant TB strains, for whom existing treatments are already failing, and may have applications against other stubborn bacterial infections.
- Human clinical trials are the critical next frontier, with Johns Hopkins researchers planning to use advanced PET imaging to track the therapy's effects on living lungs in real time.
Tuberculosis, one of humanity's oldest and most relentless adversaries, claims over a million lives each year and leaves millions more with lungs permanently scarred by the battle. Researchers at Johns Hopkins Medicine have discovered that navitoclax, a drug developed to fight cancer, may help the body reclaim control of how infected cells die — steering them away from destructive chaos and toward orderly resolution. By combining this experimental agent with standard antibiotics in mouse models, scientists observed a dramatic reduction in lung damage and bacterial burden, opening a door that host-directed therapies had never before walked through. The question now is whether what works in mice will hold in the complexity of the human body.
Tuberculosis kills more people than any other infectious disease on Earth — 1.25 million lives lost in 2023, and 10.8 million new infections. The standard six-month antibiotic regimen is grueling and expensive, and even survivors often emerge with permanent lung scarring and breathing difficulties that shadow them for years. Now, Johns Hopkins researchers have found an unlikely ally in the fight: a cancer drug called navitoclax.
The key lies in how tuberculosis bacteria survive inside the body. Once Mycobacterium tuberculosis infects lung cells, it forces them to produce proteins called Bcl-2, which block the body's natural, orderly form of cell death. Instead, infected cells die chaotically — destroying surrounding tissue, fueling inflammation, and creating hidden pockets where bacteria can multiply beyond the immune system's reach. Navitoclax blocks those Bcl-2 proteins, restoring the controlled cell-death process the body was designed to use.
In mouse studies published in Nature Communications, combining navitoclax with the three standard TB antibiotics produced striking results: a 40% reduction in destructive lung lesions, a 40% cut in lung scarring, and a bacterial burden reduced 16 times more effectively than with antibiotics alone. The infection was also less likely to spread to other organs.
Dr. Sanjay Jain, the study's senior author, sees this as a fundamental shift in strategy — targeting the infected host cells rather than the bacteria directly, an approach known as host-directed therapy. The implications reach beyond standard TB cases. Hundreds of thousands of patients carry drug-resistant strains that no longer respond to existing antibiotics, and tens of millions of survivors live with post-TB lung disease long after the infection clears.
The path forward leads to human clinical trials, where Jain's team plans to use advanced PET imaging to observe the therapy's effects in real time. If navitoclax proves safe and effective in people, it could shorten treatment, reduce permanent lung damage, and offer new hope to patients for whom medicine has long had too little to offer.
Tuberculosis kills more people than any other infectious disease on the planet. In 2023 alone, the disease claimed 1.25 million lives and infected 10.8 million new patients, according to the World Health Organization. The standard treatment—a six-month regimen of antibiotics taken daily—is grueling, expensive, and often leaves survivors with permanent lung scarring and breathing problems that can persist for years. Now researchers at Johns Hopkins Medicine have found something unexpected: a drug originally designed to fight cancer might make TB treatment faster, more effective, and less damaging to the lungs.
The drug is called navitoclax, and it works by interfering with a molecular trick that tuberculosis bacteria use to survive inside the human body. When Mycobacterium tuberculosis infects lung cells, it hijacks a natural cellular pathway by forcing infected cells to produce proteins called Bcl-2. These proteins prevent the infected cells from dying in a controlled, orderly way. Instead, the bacteria push the cells toward a chaotic form of death called necrosis—imagine a building destroyed by a bomb rather than carefully demolished. This violent cell death creates inflammation and tissue damage throughout the lung, while also creating pockets where the bacteria can hide from the immune system and multiply unchecked.
Navitoclax does the opposite. It blocks the Bcl-2 proteins and tips the balance back toward apoptosis, the body's natural, controlled form of cell death. In mouse studies published in Nature Communications in March 2025, researchers combined navitoclax with the three standard TB antibiotics—rifampin, isoniazid, and pyrazinamide. The results were striking. Mice that received both the antibiotics and navitoclax showed a 40 percent reduction in the destructive necrotic lesions in their lungs compared to mice receiving antibiotics alone. The infection was also less likely to spread to other organs like the spleen. Using advanced imaging technology, the researchers found that navitoclax doubled the amount of controlled cell death in the lungs and cut lung scarring by 40 percent. Most remarkably, the combination decreased the bacterial burden 16 times more effectively than antibiotics alone.
Dr. Sanjay Jain, the study's senior author and a pediatric infectious diseases specialist at Johns Hopkins Children's Center, emphasized the potential impact. Current TB treatments are lengthy, expensive, and leave patients vulnerable to relapse and permanent lung damage. A therapy that works with the body's own immune system rather than against the bacteria directly could transform how doctors treat the disease. The approach is called host-directed therapy because it targets the infected host cells rather than the bacteria themselves—a strategy that had never been tested alongside real-world TB treatment before this study.
The implications extend beyond tuberculosis. Hundreds of thousands of TB patients worldwide now carry drug-resistant strains that no longer respond to standard antibiotics. Post-TB lung disease, a condition affecting tens of millions of survivors, causes chronic breathing problems and reduced quality of life long after the infection is cleared. If navitoclax proves safe and effective in human clinical trials, it could shorten the standard six-month treatment course, reduce the incidence of permanent lung scarring, and offer hope to patients with resistant infections. The researchers also believe the drug might help fight other chronic bacterial infections, including certain strains of Staphylococcus aureus and non-TB mycobacteria that are increasingly common in the United States.
The next step is clear: moving from mouse models to human patients. Jain, who directs the Johns Hopkins Center for Infection and Inflammation Imaging Research, plans to use advanced PET imaging technology to track how the therapy works in real time and visualize lung scarring as it develops. If those trials succeed, navitoclax or similar drugs could eventually become part of the standard TB treatment regimen, fundamentally changing how doctors approach a disease that has plagued humanity for centuries.
Bemerkenswerte Zitate
Current treatment regimens for TB are lengthy, expensive and leave patients vulnerable to relapse and lung scarring. Adding a host-directed therapy has extraordinary promise to solve these problems.— Dr. Sanjay Jain, Johns Hopkins Children's Center
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical.net ↗
Health & Medicine